Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Evaxion Biotech ( (EVAX) ) is now available.
On January 31, 2025, Evaxion Biotech A/S closed a public offering of nearly 4 million American Depositary Shares (ADSs) and warrants, significantly increasing its share capital. The company’s Articles of Association were amended to reflect these changes, including the grant of up to 1,998,675 warrants to purchase ADSs. This restructuring aims to bolster the company’s capital for future endeavors, potentially enhancing its market position and offering new opportunities for stakeholders.
More about Evaxion Biotech
Evaxion Biotech A/S is a company operating in the biotechnology industry, primarily focused on developing advanced software to enable the creation of novel immune therapies and vaccines.
YTD Price Performance: -34.28%
Average Trading Volume: 2,372,331
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.07M
See more insights into EVAX stock on TipRanks’ Stock Analysis page.
